Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

210 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting human melanoma neoantigens by T cell receptor gene therapy.
Leisegang M, Kammertoens T, Uckert W, Blankenstein T. Leisegang M, et al. Among authors: blankenstein t. J Clin Invest. 2016 Mar 1;126(3):854-8. doi: 10.1172/JCI83465. Epub 2016 Jan 25. J Clin Invest. 2016. PMID: 26808500 Free PMC article.
In successful cancer immunotherapy, T cell responses appear to be directed toward neoantigens created by somatic mutations; however, direct evidence that neoantigen-specific T cells cause regression of established cancer is lacking. Here, we generated T cells …
In successful cancer immunotherapy, T cell responses appear to be directed toward neoantigens created by somatic mutations; however, …
Targeting cancer-specific mutations by T cell receptor gene therapy.
Blankenstein T, Leisegang M, Uckert W, Schreiber H. Blankenstein T, et al. Curr Opin Immunol. 2015 Apr;33:112-9. doi: 10.1016/j.coi.2015.02.005. Epub 2015 Feb 27. Curr Opin Immunol. 2015. PMID: 25728991 Free PMC article. Review.
The ease of sequencing the cancer genome, identifying all somatic mutations and grafting mutation-specific T cell receptor (TCR) genes into T cells for adoptive transfer allow, for the first time, a truly tumor-specific and effective therapy. ...Recent clinical data …
The ease of sequencing the cancer genome, identifying all somatic mutations and grafting mutation-specific T cell receptor (TCR) gene …
Transgenic mice with a diverse human T cell antigen receptor repertoire.
Li LP, Lampert JC, Chen X, Leitao C, Popović J, Müller W, Blankenstein T. Li LP, et al. Among authors: blankenstein t. Nat Med. 2010 Sep;16(9):1029-34. doi: 10.1038/nm.2197. Epub 2010 Aug 8. Nat Med. 2010. PMID: 20693993
Because of tolerance mechanisms, it has been hard to identify the T cell receptors (TCRs) of high-avidity T cells against self (for example, tumor) antigens. ...Functional CD8+ T cells against several human tumor antigens were induced, and those against the M …
Because of tolerance mechanisms, it has been hard to identify the T cell receptors (TCRs) of high-avidity T cells against self …
T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk.
Kunert A, Obenaus M, Lamers CHJ, Blankenstein T, Debets R. Kunert A, et al. Among authors: blankenstein t. Clin Cancer Res. 2017 Oct 15;23(20):6012-6020. doi: 10.1158/1078-0432.CCR-17-1012. Epub 2017 Jun 23. Clin Cancer Res. 2017. PMID: 28645940 Review.
Adoptive therapy with T-cell receptor (TCR)-engineered T cells has shown promising results in the treatment of patients with tumors, and the number of TCRs amenable for clinical testing is expanding rapidly. Notably, adoptive therapy with T cells is challenge …
Adoptive therapy with T-cell receptor (TCR)-engineered T cells has shown promising results in the treatment of patients with t …
Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.
Willimsky G, Schmidt K, Loddenkemper C, Gellermann J, Blankenstein T. Willimsky G, et al. Among authors: blankenstein t. J Clin Invest. 2013 Mar;123(3):1032-43. doi: 10.1172/JCI64742. Epub 2013 Feb 1. J Clin Invest. 2013. PMID: 23454765 Free PMC article.
Despite the presence of functional, antigen-specific T cells, a few virus-infected cells escaped immune clearance and progressed to HCC. ...Virus-infected mice revealed significantly greater T cell infiltration in early-stage HCC compared with that in late-stage HCC …
Despite the presence of functional, antigen-specific T cells, a few virus-infected cells escaped immune clearance and progressed to H …
Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette L, Chen X, Lorenz FK, Blankenstein T. Poncette L, et al. Among authors: blankenstein t. J Clin Invest. 2019 Jan 2;129(1):324-335. doi: 10.1172/JCI120391. Epub 2018 Dec 10. J Clin Invest. 2019. PMID: 30530988 Free PMC article.
T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang M, Turqueti-Neves A, Engels B, Blankenstein T, Schendel DJ, Uckert W, Noessner E. Leisegang M, et al. Among authors: blankenstein t. Clin Cancer Res. 2010 Apr 15;16(8):2333-43. doi: 10.1158/1078-0432.CCR-09-2897. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371691
PURPOSE: Adoptive therapy with genetically engineered T cells carrying redirected antigen specificity is a new option for the treatment of cancer. ...We analyzed tumor-infiltrating lymphocytes (TIL) from RCC to identify T-cell specificities with shared tumor-specifi …
PURPOSE: Adoptive therapy with genetically engineered T cells carrying redirected antigen specificity is a new option for the treatme …
Designer T cells by T cell receptor replacement.
Sommermeyer D, Neudorfer J, Weinhold M, Leisegang M, Engels B, Noessner E, Heemskerk MH, Charo J, Schendel DJ, Blankenstein T, Bernhard H, Uckert W. Sommermeyer D, et al. Among authors: blankenstein t. Eur J Immunol. 2006 Nov;36(11):3052-9. doi: 10.1002/eji.200636539. Eur J Immunol. 2006. PMID: 17051621
T cell receptor (TCR) gene transfer is a convenient method to produce antigen-specific T cells for adoptive therapy. However, the expression of two TCR in T cells could impair their function or cause unwanted effects by mixed TCR heterodimers. ...A mouse TCR
T cell receptor (TCR) gene transfer is a convenient method to produce antigen-specific T cells for adoptive therapy. However,
Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
Textor A, Listopad JJ, Wührmann LL, Perez C, Kruschinski A, Chmielewski M, Abken H, Blankenstein T, Charo J. Textor A, et al. Among authors: blankenstein t. Cancer Res. 2014 Dec 1;74(23):6796-805. doi: 10.1158/0008-5472.CAN-14-0079. Epub 2014 Oct 8. Cancer Res. 2014. PMID: 25297631
Adoptive T-cell therapy using chimeric antigen receptor-modified T cells (CAR-T therapy) has shown dramatic efficacy in patients with circulating lymphoma. However, eradication of solid tumors with CAR-T therapy has not been reported yet to be efficaci …
Adoptive T-cell therapy using chimeric antigen receptor-modified T cells (CAR-T therapy) has shown dramatic efficacy in …
Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells.
Pinto S, Sommermeyer D, Michel C, Wilde S, Schendel D, Uckert W, Blankenstein T, Kyewski B. Pinto S, et al. Among authors: blankenstein t. Eur J Immunol. 2014 Sep;44(9):2811-21. doi: 10.1002/eji.201444499. Epub 2014 Aug 18. Eur J Immunol. 2014. PMID: 24846220 Clinical Trial.
Immunity to tumor differentiation antigens, such as melanoma antigen recognized by T cells 1 (MART-1), has been comprehensively studied. Intriguingly, CD8(+) T cells specific for the MART-1(26(27)-35) epitope in the context of HLA-A0201 are about 100 times more abun …
Immunity to tumor differentiation antigens, such as melanoma antigen recognized by T cells 1 (MART-1), has been comprehensively studi …
210 results
Jump to page
Feedback